Summaries of review for applications to RFA 10-05 Disease Team Therapy Development Awards

Review Summaries for RFA 10-05: CIRM Disease Team Therapy Development Awards

The following is a listing of all applications reviewed under RFA 10-05 for CIRM Disease Team Therapy Development Awards. Applications include the score (between 0 and 100, with 100 being the best) and a funding recommendation (indicated by the color key below) made by the Grants Working Group (GWG). A link to the Public Abstract (provided by applicant), Statement of Benefit to California (provided by applicant), and Public Review Report are available for each application by clicking on the respective application number.

 
= Recommended for funding  
 
= Not Recommended for funding at this time
Application Number Approval Title Scientific Score
DR2-05352 Approved [REDACTED]: A New Cancer Therapeutic to Reduce CSC Frequency 87
DR2-05298 Approved Airways for Children 85
DR2-05423 Approved Phase I study of IM Injection of VEGF Producing MSC for the Treatment of Critical Limb Ischemia 83
DR2-05327 Approved Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients 83
DR2-05309 Approved Genetic Re-programming of Stem Cells to Fight Cancer 80
DR2-05416 Approved Neuroprotection to treat Alzheimer's: a new paradigm using human central nervous system cells 79
DR2-05394 Approved Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure 79
DR2-05434 Approved Preclinical Development and First-In-Human Testing of [REDACTED] in Advanced Heart Failure 79
DR2-05415 Approved MSC engineered to produce BDNF for the treatment of Huntington's disease 76
DR2-05320 Approved Stem Cells Secreting GDNF for the Treatment of ALS 72
DR2-05365 Approved A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants 72
DR2-05302 Approved Increasing the endogenous mesenchymal stem cells to the bone surface to treat osteoporosis 72
DR2-05288 Approved Genetically Engineered Mesenchymal Stem Cells for the Treatment of Vertebral Compression Fractures. 71
DR2-05368  Approved Clinical Development of an osteoinductive therapy to prevent osteoporosis-related fractures 69
DR2-05410 Approved A CIRM Disease Team to Develop Allopregnanolone for Prevention and Treatment of Alzheimer's Disease 69
DR2-05357   Neural Stem Cell-Mediated Therapy for Pediatric Brain Tumors -
DR2-05373 Approved Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma 65
DR2-05431 Approved Neural Stem Cell-Based Therapy For Parkinson's Disease 63
DR2-05272 Approved hESC-derived NPCs Programmed with MEF2C for Cell Transplantation in Parkinson's Disease 62
DR2-05432   Phase I/II clinical trial targeting Hedgehog pathway in medulloblastoma cancer stem cells -
DR2-05426 Approved Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy 57
DR2-05393   Targeting nanotherapeutics to eradicate leukemia stem cells. -
DR2-05346   Regenerating Bone in Patients with Osteoporosis -
DR2-05401   Heart-derived cells in hydrogel for cardiac regeneration -
DR2-05360   Clinical Development of Gene Modified Mesenchymal Stromal Cells for Stroke Disability -
DR2-05419   Use of Oncocidal Human Neural Stem Cells to Target Breast Cancer Brain Metastasis -
DR2-05310   Mesenchymal Stem Cells Producing IGF-1 for the Treatment of ALS. -
DR2-05312   Genetically Engineering Stem Cells to Target HIV Infection -
DR2-05279   Use of Human Neural Stem Cells for Neuroprotection Following Hypothermia In Sub-acute Neonatal -
DR2-05318   Osteosarcoma stem cell-targeted therapy using novel retinoid agonist -
DR2-05329   Pim-1 Enhanced Adult Cardiac Stem Cells: Clinical Therapy for Myocardial Regeneration -
DR2-05420   Clinical evaluation of human neural stem cells as a treatment for age-related macular degeneration -
DR2-05399   Preclinical Development of hES-Derived Clonal Embryonic Progenitors for Joint Regeneration -
DR2-05406   Bioengineering implantable bone tissue for treating nonhealing defects -
DR2-05341   Development of iPS Cell-based Therapy for Cerebral Palsy -
DR2-05314   Autologous Adult Human Neural Stem Cell-derived Neurons for the Treatment of Parkinson's disease -